Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
27 Jun 2024
27 Jun 2024
Historique:
accepted:
03
06
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
27
6
2024
Statut:
aheadofprint
Résumé
Trastuzumab targets human epidermal growth factor receptor 2 (HER2) receptors and is indicated for treating HER2-positive metastatic breast cancer. BP02, a recombinant IgG1 kappa humanized monoclonal antibody, is being developed as a trastuzumab biosimilar. The objective of this study was to evaluate the equivalence of BP02 with reference trastuzumab (RT: Herceptin This double-blinded, 1:1 randomized, parallel-group, active-controlled, phase III equivalence trial recruited women aged 18-75 years with histologically/cytologically confirmed HER2- positive, locally recurrent or metastatic breast cancer with systemic metastasis, from 59 sites in India. Patients were randomly allocated 1:1 stratified by estrogen receptor/progesterone receptor status to receive BP02/RT (8-mg/kg loading dose on day 1-cycle 1, 6 mg/kg on day 1-cycles 2-8, of each 3-week cycle) combined with docetaxel (75 mg/m Between 23 September, 2020 and 16 September, 2022, 690 patients were recruited (n = 345 each to BP02/RT). At the end of the induction phase (intent-to-treat population), a similar proportion of patients achieved an objective response rate with BP02 (n = 231 [67.0%], 95% confidence interval [CI] 62.0, 71.9) and RT (n = 238 [69.0%], 95% CI 64.1, 73.9). The 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) and 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) were within equivalence margins of ± 13% and (0.80, 1.25), respectively. Treatment-emergent adverse events leading to treatment withdrawal were reported in 2.9% and 3.2% patients with BP02 and RT, respectively. BP02 showed an equivalent efficacy and similar safety profile to RT at the end of 24 weeks. CTRI Number: CTRI/2020/04/024456.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Trastuzumab targets human epidermal growth factor receptor 2 (HER2) receptors and is indicated for treating HER2-positive metastatic breast cancer. BP02, a recombinant IgG1 kappa humanized monoclonal antibody, is being developed as a trastuzumab biosimilar. The objective of this study was to evaluate the equivalence of BP02 with reference trastuzumab (RT: Herceptin
METHODS
METHODS
This double-blinded, 1:1 randomized, parallel-group, active-controlled, phase III equivalence trial recruited women aged 18-75 years with histologically/cytologically confirmed HER2- positive, locally recurrent or metastatic breast cancer with systemic metastasis, from 59 sites in India. Patients were randomly allocated 1:1 stratified by estrogen receptor/progesterone receptor status to receive BP02/RT (8-mg/kg loading dose on day 1-cycle 1, 6 mg/kg on day 1-cycles 2-8, of each 3-week cycle) combined with docetaxel (75 mg/m
RESULTS
RESULTS
Between 23 September, 2020 and 16 September, 2022, 690 patients were recruited (n = 345 each to BP02/RT). At the end of the induction phase (intent-to-treat population), a similar proportion of patients achieved an objective response rate with BP02 (n = 231 [67.0%], 95% confidence interval [CI] 62.0, 71.9) and RT (n = 238 [69.0%], 95% CI 64.1, 73.9). The 95% CI of risk difference (-2.03, 95% CI -9.15, 5.09) and 90% CI of risk ratio (0.97, 90% CI 0.89, 1.06) were within equivalence margins of ± 13% and (0.80, 1.25), respectively. Treatment-emergent adverse events leading to treatment withdrawal were reported in 2.9% and 3.2% patients with BP02 and RT, respectively.
CONCLUSIONS
CONCLUSIONS
BP02 showed an equivalent efficacy and similar safety profile to RT at the end of 24 weeks.
CLINICAL TRIAL REGISTRATION
BACKGROUND
CTRI Number: CTRI/2020/04/024456.
Identifiants
pubmed: 38937403
doi: 10.1007/s40261-024-01374-y
pii: 10.1007/s40261-024-01374-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19(1):40–50.
pubmed: 33493147
Kumar RV, Panwar D, Amirtham U, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: a retrospective study of 5436 women from a regional cancer center in South India. South Asian J Cancer. 2018;7(1):7–10.
doi: 10.4103/sajc.sajc_211_17
pubmed: 29600224
pmcid: 5865104
Doval DC, Radhakrishna S, Tripathi R, et al. A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery. Sci Rep. 2020;10(1):5886.
doi: 10.1038/s41598-020-62618-3
pubmed: 32246015
pmcid: 7125186
Fabi A, Malaguti P, Vari S, et al. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? J Exp Clin Cancer Res. 2016;35:104.
doi: 10.1186/s13046-016-0380-5
pubmed: 27357210
pmcid: 4928292
Albagoush SA, Limaiem F. HER2. Treasure Island: StatPearls Publishing LLC; 2023.
Pimentel FF, Morgan G, Tiezzi DG, et al. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceut Med. 2018;32(5):319–25.
pubmed: 30363808
pmcid: 6182492
Greenblatt K, Khaddour K. Trastuzumab. Treasure Island: StatPearls Publishing LLC; 2023.
Lammers P, Criscitiello C, Curigliano G, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7(9):943–53.
doi: 10.3390/ph7090943
pubmed: 25232798
Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. US FDA; 2015. https://www.fda.gov/media/82647/download . Accessed 08 Mar 2024.
Guideline on similar biological medicinal products. European Medicines Agency; 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf . Accessed 08 Mar 2024.
Summary of product characteristics: herceptin. European Medicines Agency; 2010. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf . Accessed 08 Mar 2024.
Assessment report: trazimera. 2018. European Medicines Agency; 2018. https://www.ema.europa.eu/en/documents/assessment-report/trazimera-epar-public-assessment-report_en.pdf . Accessed 08 Mar 2024.
Integrated addendum to ICH E6(R1): guideline for good clinical practice E6 (R2). 2016. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf . Accessed 08 Mar 2024.
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency; 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf . Accessed 08 Mar 2024.
Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. US FDA; 2018. https://www.fda.gov/media/71195/download . Accessed 08 Mar 2024.
Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017;317(1):37–47.
doi: 10.1001/jama.2016.18305
pubmed: 27918780
Pegram MD, Bondarenko I, Zorzetto MMC, et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer. 2019;120(2):172–82.
doi: 10.1038/s41416-018-0340-2
pubmed: 30568294
Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18(7):917–28.
doi: 10.1016/S1470-2045(17)30434-5
pubmed: 28592386
Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018;36(10):968–74.
doi: 10.1200/JCO.2017.74.0126
pubmed: 29373094
Stebbing J, Mainwaring PN, Curigliano G, et al. Understanding the role of comparative clinical studies in the development of oncology biosimilars. J Clin Oncol. 2020;38(10):1070–80.
doi: 10.1200/JCO.19.02953
pubmed: 32058846
pmcid: 7106981
Uifălean A, Ilieş M, Nicoară R, et al. Concepts and challenges of biosimilars in breast cancer: the emergence of trastuzumab biosimilars. Pharmaceutics. 2018;10(4):168.
doi: 10.3390/pharmaceutics10040168
pubmed: 30257528
pmcid: 6321008
Blackwell K, Gligorov J, Jacobs I, et al. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018;18(2):95–113.
doi: 10.1016/j.clbc.2018.01.006
pubmed: 29525430
Bazargani YT, de Boer A, Schellens JH, et al. Essential medicines for breast cancer in low and middle income countries. BMC Cancer. 2015;15:591.
doi: 10.1186/s12885-015-1583-4
pubmed: 26283654
pmcid: 4538762
Yang C, Khwaja R, Tang P, et al. A review of trastuzumab biosimilars in early breast cancer and real world outcomes of neoadjuvant MYL-1401O versus reference trastuzumab. Curr Oncol. 2022;29(6):4224–34.
doi: 10.3390/curroncol29060337
pubmed: 35735446
pmcid: 9221768